MA41759A - Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide - Google Patents
Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acideInfo
- Publication number
- MA41759A MA41759A MA041759A MA41759A MA41759A MA 41759 A MA41759 A MA 41759A MA 041759 A MA041759 A MA 041759A MA 41759 A MA41759 A MA 41759A MA 41759 A MA41759 A MA 41759A
- Authority
- MA
- Morocco
- Prior art keywords
- glucosidase
- inclusion
- exon
- antisens
- induced
- Prior art date
Links
- 108010028144 alpha-Glucosidases Proteins 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 abstract 3
- 102000016679 alpha-Glucosidases Human genes 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 2
- 101150115151 GAA gene Proteins 0.000 abstract 1
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000007345 glycogen storage disease Diseases 0.000 abstract 1
- 201000004502 glycogen storage disease II Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des oligomères antisens et des compositions apparentées et des procédés d'induction d'inclusion d'exon en tant que traitement pour la maladie de stockage du glycogène de type ii (gsd-ii) (également appelée maladie de pompe, glycogénose ii, déficit en acide maltase, déficience en glucosidase, et déficience en alpha-glucosidase lysosomale), et plus spécifiquement concerne l'induction de l'inclusion de l'exon 2 et ainsi la restauration des niveaux de la protéine alpha-glucosidase acide (gaa) enzymatiquement active codée par le gène gaa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126346P | 2015-02-27 | 2015-02-27 | |
| US201562234263P | 2015-09-29 | 2015-09-29 | |
| US201662300635P | 2016-02-26 | 2016-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41759A true MA41759A (fr) | 2018-01-03 |
Family
ID=56789314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041759A MA41759A (fr) | 2015-02-27 | 2016-02-29 | Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180216111A1 (fr) |
| EP (1) | EP3262056A4 (fr) |
| JP (4) | JP2018509143A (fr) |
| AU (2) | AU2016224976A1 (fr) |
| BR (1) | BR112017018383B1 (fr) |
| CA (1) | CA2977528A1 (fr) |
| HK (1) | HK1249106A1 (fr) |
| IL (2) | IL254112B (fr) |
| MA (1) | MA41759A (fr) |
| MX (2) | MX2017011004A (fr) |
| TW (2) | TW201702378A (fr) |
| WO (1) | WO2016138534A2 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014317961B2 (en) | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| KR102620328B1 (ko) | 2014-10-03 | 2024-01-02 | 콜드스프링하버러보러토리 | 핵 유전자 산출량의 표적화 증강 |
| HRP20231431T1 (hr) | 2015-05-19 | 2024-03-01 | Sarepta Therapeutics, Inc. | Peptidno oligonukleotidni konjugati |
| SG11201802870RA (en) | 2015-10-09 | 2018-05-30 | Univ Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3390636B1 (fr) | 2015-12-14 | 2021-05-19 | Cold Spring Harbor Laboratory | Oligomères antisens destinés au traitement du syndrome de dravet |
| CA3006748A1 (fr) * | 2015-12-15 | 2017-06-22 | Sarepta Therapeutics, Inc. | Conjugues peptide-oligonucleotide |
| BR112018071477A2 (pt) | 2016-04-18 | 2019-02-19 | Sarepta Therapeutics, Inc. | oligômeros antisenso e métodos de utilização dos mesmos para tratamento de doenças associadas com o gene da alfa-glicosidase ácida |
| NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
| NL2017295B1 (en) * | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
| CA3073515A1 (fr) | 2017-08-25 | 2019-02-28 | Stoke Therapeutics, Inc. | Oligomeres antisens pour le traitement d'etats pathologiques et autres maladies |
| US20210102205A1 (en) * | 2018-04-26 | 2021-04-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
| EP3788169A4 (fr) | 2018-05-04 | 2022-08-10 | Stoke Therapeutics, Inc. | Méthodes et compositions pour le traitement d'une maladie de stockage d'ester de cholestéryle |
| TW202449155A (zh) * | 2018-07-27 | 2024-12-16 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| CN113748209A (zh) | 2019-02-27 | 2021-12-03 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| JP2022551986A (ja) | 2019-10-16 | 2022-12-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | 修飾筋肉標的化組成物 |
| KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2023283629A1 (fr) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs formulations pour traiter la dystrophie musculaire facio-scapulo-humérale |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CA3233242A1 (fr) * | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Oligonucleotides antisens ayant une ou plusieurs unites abasiques |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| JP2025524656A (ja) | 2022-07-14 | 2025-07-30 | ザ・ブロード・インスティテュート・インコーポレイテッド | トランスフェリン受容体との相互作用を通じてｃｎｓ全体への遺伝子送達を可能にするａａｖキャプシド |
| WO2025155923A1 (fr) | 2024-01-17 | 2025-07-24 | The Broad Institute, Inc. | Modifications de capsides de vaa permettant une administration améliorée de gènes à l'échelle du snc par l'intermédiaire d'interactions avec le récepteur de la transferrine |
| WO2025217163A2 (fr) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Nouveaux capsides aav se liant à cd59 humain |
| WO2025217174A1 (fr) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Modifications de capside d'aav qui permettent une délivrance améliorée de gènes à l'échelle du snc par l'intermédiaire d'interactions avec l'anhydrase carbonique iv |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1922313B (zh) * | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| KR20200133284A (ko) * | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CN107693797B (zh) * | 2011-05-05 | 2021-05-11 | 萨勒普塔医疗公司 | 肽寡核苷酸缀合物 |
| KR102142689B1 (ko) * | 2011-11-18 | 2020-08-10 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| CN105378081B (zh) * | 2013-03-14 | 2019-06-14 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| AU2014317961B2 (en) * | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US9790495B2 (en) * | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| WO2015190922A1 (fr) * | 2014-06-10 | 2015-12-17 | Erasmus University Medical Center Rotterdam | Oligonucléotides antisens utilisés dans le traitement de la maladie de pompe |
-
2016
- 2016-02-29 HK HK18108560.3A patent/HK1249106A1/zh unknown
- 2016-02-29 JP JP2017545273A patent/JP2018509143A/ja not_active Ceased
- 2016-02-29 WO PCT/US2016/020127 patent/WO2016138534A2/fr not_active Ceased
- 2016-02-29 EP EP16756555.5A patent/EP3262056A4/fr active Pending
- 2016-02-29 AU AU2016224976A patent/AU2016224976A1/en not_active Abandoned
- 2016-02-29 BR BR112017018383-8A patent/BR112017018383B1/pt active IP Right Grant
- 2016-02-29 MX MX2017011004A patent/MX2017011004A/es unknown
- 2016-02-29 CA CA2977528A patent/CA2977528A1/fr active Pending
- 2016-02-29 US US15/553,911 patent/US20180216111A1/en not_active Abandoned
- 2016-02-29 MA MA041759A patent/MA41759A/fr unknown
- 2016-03-01 TW TW105106275A patent/TW201702378A/zh unknown
- 2016-03-01 TW TW112123102A patent/TW202403045A/zh unknown
-
2017
- 2017-08-23 IL IL254112A patent/IL254112B/en active IP Right Grant
- 2017-08-25 MX MX2024010190A patent/MX2024010190A/es unknown
-
2020
- 2020-06-10 AU AU2020203825A patent/AU2020203825B2/en active Active
-
2021
- 2021-03-02 IL IL281199A patent/IL281199B/en unknown
- 2021-07-12 JP JP2021114792A patent/JP2021166543A/ja active Pending
-
2023
- 2023-07-14 JP JP2023115841A patent/JP2023129494A/ja active Pending
-
2024
- 2024-04-03 JP JP2024060083A patent/JP2024074908A/ja active Pending
- 2024-05-10 US US18/660,789 patent/US20250171783A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL254112A (en) | 2018-06-28 |
| JP2023129494A (ja) | 2023-09-14 |
| US20250171783A1 (en) | 2025-05-29 |
| JP2021166543A (ja) | 2021-10-21 |
| US20180216111A1 (en) | 2018-08-02 |
| EP3262056A2 (fr) | 2018-01-03 |
| IL281199B (en) | 2022-05-01 |
| TW201702378A (zh) | 2017-01-16 |
| CA2977528A1 (fr) | 2016-09-01 |
| WO2016138534A3 (fr) | 2016-12-22 |
| HK1249106A1 (zh) | 2018-10-26 |
| BR112017018383A2 (pt) | 2018-09-04 |
| WO2016138534A2 (fr) | 2016-09-01 |
| MX2024010190A (es) | 2024-08-28 |
| AU2020203825B2 (en) | 2021-08-05 |
| AU2020203825A1 (en) | 2020-07-02 |
| MX2017011004A (es) | 2018-02-09 |
| IL254112B (en) | 2021-04-29 |
| BR112017018383B1 (pt) | 2023-04-25 |
| JP2018509143A (ja) | 2018-04-05 |
| EP3262056A4 (fr) | 2018-09-19 |
| TW202403045A (zh) | 2024-01-16 |
| JP2024074908A (ja) | 2024-05-31 |
| AU2016224976A1 (en) | 2017-09-14 |
| IL281199A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41759A (fr) | Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide | |
| EP2493507A4 (fr) | Antagonistes et variants ax213 et ax132 pcsk9 | |
| EA201001393A1 (ru) | Липазы с высокой специфичностью к жирным кислотам с короткой цепью и их использование | |
| MA35125B1 (fr) | Alpha glucosidase acide modifiee a traitement accelere | |
| EA201792663A1 (ru) | Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr | |
| CO6700848A2 (es) | Formulaciones recubiertas entéricas de pancrelipilasa, de baja intensidad | |
| MX336731B (es) | Composiciones y metodos para potenciar la actividad de proteasoma. | |
| ATE516353T1 (de) | Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs | |
| MA38406B1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
| EP2823043A4 (fr) | Compositions d'alpha-glucosidase à haute concentration pour le traitement de la maladie de pompe | |
| MY162056A (en) | Diagnosis and treatment of cancer using anti -ereg antibody | |
| MA37975B2 (fr) | Inhibiteurs de synthase de glucosylcéramide | |
| EA200870528A1 (ru) | Композиции и способы ингибирования экспрессии гена pcsk9 | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| MA33488B1 (fr) | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn | |
| EA201891507A1 (ru) | Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе | |
| IN2012DN00801A (fr) | ||
| EA200601823A1 (ru) | Новые липазы и их применение | |
| MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli | |
| MA44593B1 (fr) | Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations | |
| SI2751279T1 (en) | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use | |
| CA3156499A1 (fr) | Analogues chinone, hydrochinone et naphtochinone de vatiquinone pour le traitement de maladies a troubles mitochondriaux | |
| EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
| EA200971059A1 (ru) | Лечение и профилактика гриппа |